Skip to main content
Equibles
NVS logo

NVS · Novartis AG

Track NVS — free

Use NVS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NVS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$150.88 -0.84 (-0.55%) At close · Aug 14
Market Cap
$286.78B
Shares
1.90B

Novartis AG Earnings Call Transcripts

Every quarterly earnings call for Novartis AG (NVS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q4
2025-12-31
Novartis AG Q4 FY2025 Earnings Call
Confident tone Kisqali growth and peak sales outlook Remibrutinib and pelabresib pipeline progress Avidity acquisition / SG&A and margin dilution
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Novartis AG Q3 FY2025 Earnings Call
Confident tone Full-year 2025 guidance and margin outlook Generic erosion of legacy brands Late-stage pipeline and approvals
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Novartis AG Q2 FY2025 Earnings Call
Confident tone Priority brands momentum Topline and margin growth Entresto generic risk and IP defense
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Novartis AG Q1 FY2025 Earnings Call
Confident tone Kisqali momentum in metastatic and early breast cancer Pluvicto PSMAfore launch and radioligand expansion Pipeline and regulatory milestones
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Novartis AG Q4 FY2024 Earnings Call
Confident tone Key growth brands (Cosentyx, Kesimpta, Kisqali) Pluvicto and radioligand therapy (RLT) pipeline Pipeline readouts and innovation momentum
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Novartis AG Q3 FY2024 Earnings Call
Confident tone Kisqali early breast cancer launch Entresto growth and loss of exclusivity IRA legislation and siRNA policy
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Novartis AG Q2 FY2024 Earnings Call
Confident tone Growth drivers and brand momentum Pluvicto / radioligand therapy Remibrutinib manufacturing delay
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Novartis AG Q1 FY2024 Earnings Call
Confident tone Leqvio geographic ramp Cosentyx and new indications Kisqali and early breast cancer
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Novartis AG Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Novartis AG Q3 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Novartis AG Q1 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 earnings calls
Key facts CIK 1114448 CUSIP 66987V109 13F (30d) 1380 filings 1339 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)